Kissei Sales Better Than Expected
In the first four months of the current financial year, (which ends in March 1995) sales by Japanese company Kissei Pharmaceutical of its major products were better than had been first expected.
Analysts at Lehman Brothers recently visited the company, and they say that sales of Kissei's principal drugs should record year-on-year growth for the time being and that it should report positive growth in revenues and earnings. The analysts are now looking for results for the financial year to be higher than they had previously expected, and have upgraded their rating for the company from a moderate 3 rating to a moderate 2.
Recently, Kissei's share price fell to 3,650 yen, but the analysts say that the decline has increased the share price's upward potential to over 10%. They say that the fall in the share price was mainly due to three factors:
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze